Deerfield Management Company, L.P. (Series C) Ventyx Biosciences, Inc. Call Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.76 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VTYX
# of Institutions
122Shares Held
57.4MCall Options Held
222KPut Options Held
269K-
Ken Griffin Citadel Advisors LLC | Chicago, Il5.76MShares$12.7 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA5.25MShares$11.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$10.5 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$7.01 Million0.04% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$6.85 Million0.87% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $125M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...